This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
(OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinicaltrial on neuropathic and post-operative pain.
They are learning quickly from the successes and failures in Canada’s legal medical cannabis program that has been active since 2001. The roadmap ahead includes clinicaltrials and more research in Denmark. Arundati Dandapani. Founder and CEO, . Generation1.ca. C) 613-890-7133. (T) T) @itadnura.
Note: No human studies were found (with the exception of one clinicaltrial that was ongoing and therefore not selected); all studies focused on animals (i.e., Exploring alternative therapies, researchers turned their attention to marijuana cannabinoid, cannabidiol – more commonly referred to as CBD. mice/rats).
Only one article appeared in the MJA in 2000 and again in 2001. Less frequent were references to multiple sclerosis, anxiety and depression, sleep, and HIV. It is unclear whether doctors are feeling completely reassured by laboratory and clinicaltrial research into medicinal cannabis. Full size image.
The ECS touches on nearly every biological function you have, including sleep, pain, appetite, body temperature, immune function, memory, and hormone regulation. 10 A 2001 review paper by cannabis researcher Dr. Ethan Russo details the historical use of cannabis for migraines.
Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinicaltrials and international studies. Rick Doblin, Ph.D, in/rickdoblin/ [link]. Drug Science. Matthew Johnson. Johns Hopkins University. in/ingmargorman/ [link].
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content